FY2025 EPS Estimate for Cabaletta Bio Decreased by Analyst

Cabaletta Bio, Inc. (NASDAQ:CABA) – Analysts at HC Wainwright lowered their FY2025 earnings estimates for shares of Cabaletta Bio in a report released on Tuesday, November 11th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($2.34) for the year, down from their prior forecast of ($2.32). HC Wainwright currently has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q4 2025 earnings at ($0.46) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.89) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($1.86) EPS and FY2029 earnings at ($0.92) EPS.

Other analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a report on Wednesday, October 8th. Jefferies Financial Group began coverage on shares of Cabaletta Bio in a report on Friday, October 10th. They set a “buy” rating and a $14.00 price target for the company. Finally, Cantor Fitzgerald raised their price target on Cabaletta Bio from $15.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.11.

Cabaletta Bio Stock Performance

Shares of NASDAQ:CABA traded down $0.08 during trading on Thursday, hitting $2.37. The company’s stock had a trading volume of 353,263 shares, compared to its average volume of 2,218,851. The company has a market capitalization of $228.14 million, a PE ratio of -0.94 and a beta of 3.10. The stock’s 50-day moving average price is $2.40 and its two-hundred day moving average price is $1.91. Cabaletta Bio has a fifty-two week low of $0.99 and a fifty-two week high of $5.46.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.05.

Institutional Trading of Cabaletta Bio

A number of institutional investors have recently modified their holdings of the company. Bain Capital Life Sciences Investors LLC boosted its holdings in Cabaletta Bio by 250.5% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 9,677,125 shares of the company’s stock worth $14,709,000 after purchasing an additional 6,916,237 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Cabaletta Bio by 142.9% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock valued at $13,421,000 after purchasing an additional 5,195,285 shares during the last quarter. Jennison Associates LLC raised its holdings in Cabaletta Bio by 147.4% in the 2nd quarter. Jennison Associates LLC now owns 6,020,167 shares of the company’s stock valued at $9,151,000 after acquiring an additional 3,586,439 shares during the period. Jefferies Financial Group Inc. acquired a new position in shares of Cabaletta Bio in the second quarter valued at about $3,036,000. Finally, Vanguard Group Inc. increased its position in shares of Cabaletta Bio by 21.4% in the third quarter. Vanguard Group Inc. now owns 4,190,759 shares of the company’s stock worth $9,806,000 after purchasing an additional 740,032 shares during the period.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.